Heron Therapeutics (NASDAQ: HRTX) announced positive, top-line results from its Phase 2 clinical study of HTX-011 in the management of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Heron Therapeutics' (HRTX) Price Target Raised to $54 at BofA/Merrill LynchSeptember 23, 2015 1:25 PM Brean Capital Raises Price Target on Heron Therapeutics (HRTX) Following Positive HTX-011 Results September 23, 2015 11:00 AM Leerink Boosts PT on Heron Therapeutics (HRTX) to $57 Following HTX-011 Phase 2 Top-Line ResultsSeptember 23, 2015 6:50 AM Heron Therapeutics (HRTX) PT Lifted to $58 at Jefferies Following Positive DataSeptember 23, 2015 6:46 AM Heron Therapeutics (HRTX) Announces Top-Line Results From Phase 2 Study of HTX-011 in Post-Operative PainSeptember 22, 2015 4:06 PM Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Study of HTX-011 in the Management of Post-Operative PainSeptember 22, 2015 4:05 PM Heron Therapeutics (HRTX) to Present SUSTOL Data as CINV Prevention at ASCO 2015 Breast Cancer SymposiumSeptember 22, 2015 8:06 AM